Overview
Gliclazide is an oral anti-diabetic medication belonging to the sulfonylurea class. It is widely used in the management of type 2 diabetes mellitus to improve glycemic control.

Mechanism of Action
It works by binding to sulfonylurea receptors on the pancreatic beta cells, which leads to the closure of ATP-sensitive potassium channels. This causes cell depolarization, opening of calcium channels, and ultimately triggers the release of insulin from the pancreas.

Dosage and Administration
The dosage is individualized based on blood glucose levels. The usual starting dose is 40 to 80 mg daily, taken with breakfast. The dose can be adjusted gradually, with a maximum recommended daily dose of 320 mg. Modified-release formulations are also available, usually taken once daily.

Side Effects
The most common side effect is hypoglycemia (low blood sugar), especially if meals are skipped or after intense exercise. Other potential side effects include weight gain, gastrointestinal disturbances such as nausea and diarrhea, and rare allergic skin reactions.

Contraindications
It is contraindicated in patients with type 1 diabetes, diabetic ketoacidosis, severe renal or hepatic impairment, and known hypersensitivity to sulfonylureas.

Pregnancy and Lactation
Gliclazide is generally not recommended during pregnancy, and insulin is typically preferred for blood sugar control in pregnant women. It is also contraindicated during breastfeeding due to the risk of neonatal hypoglycemia.